Eisai and Biogen received US regulatory approval for a new self-injected form of their Alzheimer’s drug Leqembi, in a move that could make a complicated treatment regimen more convenient for patients taking the drug long term https://t.co/3TkmmUjTiT ...

Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into treatments for Alzheimer’s disease and expand into immune diseases.https://t.co/1bBd93vmef https://t.co/Dtw8pt4XG9 ...